+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Denosumab"

Denosumab Market Report 2025 - Product Thumbnail Image

Denosumab Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Osteoporosis Drugs Market Report 2025 - Product Thumbnail Image

Osteoporosis Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Osteoporosis Treatment Market Report 2025 - Product Thumbnail Image

Osteoporosis Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Osteoporosis - Pipeline Insight, 2024 - Product Thumbnail Image

Osteoporosis - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 80 Pages
  • Global
From
From
Osteogenesis imperfecta (OI) - Pipeline Insight, 2024 - Product Thumbnail Image

Osteogenesis imperfecta (OI) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Bone Metastases - Pipeline Insight, 2024 - Product Thumbnail Image

Bone Metastases - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Postmenopausal Osteoporosis - Pipeline Insight, 2025 - Product Thumbnail Image

Postmenopausal Osteoporosis - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 60 Pages
  • Global
From
Osteoporosis: Seven-Market Drug Forecast and Market Analysis - Product Thumbnail Image

Osteoporosis: Seven-Market Drug Forecast and Market Analysis

  • Report
  • June 2024
  • 105 Pages
  • Global
From
From
From
From
From
Disease Analysis: Osteoporosis - Product Thumbnail Image

Disease Analysis: Osteoporosis

  • Report
  • March 2021
  • 48 Pages
  • Global
Loading Indicator

Denosumab is a monoclonal antibody used to treat endocrine and metabolic disorders. It is used to treat osteoporosis, Paget's disease of bone, and bone metastases from solid tumors. It works by inhibiting the activity of osteoclasts, which are cells that break down bone. This helps to reduce bone loss and increase bone density. Denosumab is administered as an injection under the skin or into a vein. Denosumab is a relatively new drug, and is still in the process of being approved for use in various countries. It is currently approved in the United States, Canada, Europe, and other countries. It is also being studied for use in other endocrine and metabolic disorders. Some companies in the Denosumab market include Amgen, Novartis, and Merck. Show Less Read more